{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:02:20Z","timestamp":1789945340082,"version":"4.0.1"},"reference-count":31,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,6,14]],"date-time":"2017-06-14T00:00:00Z","timestamp":1497398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Heavily pretreated patients with relapsed and refractory multiple myeloma are susceptible to treatment\u2010related adverse events (AEs). Managing AEs are important to ensure patients continue therapy long enough to receive the best clinical benefit. Data from the MM\u2010002, MM\u2010003, and MM\u2010010 trials were pooled to further characterize the safety profile of pomalidomide plus low\u2010dose dexamethasone and AE management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This analysis included 1088 patients who received \u2265 2 prior therapies, including lenalidomide and bortezomib, and progressed \u2264 60\u00a0days of last therapy. Patients received 28\u2010day cycles of pomalidomide 4\u00a0mg\/day on days 1\u201021 and low\u2010dose dexamethasone 40\u00a0mg (20\u00a0mg if aged &gt; 75\u00a0years) weekly until disease progression or unacceptable toxicity. Thromboprophylaxis was required.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The most common grade 3\/4 AEs were neutropenia (56.2%), anemia (32.3%), and thrombocytopenia (25.8%), which occurred within the first few cycles of treatment. Grade 3\/4 infections occurred in 33.7% patients, of whom 13.9% had pneumonia, and 40.3% had neutropenia. Pomalidomide dose reductions or interruptions were reported in 24.2% and 66.0% of patients, respectively. AEs were managed by dose modifications and\/or supportive care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Pomalidomide plus low\u2010dose dexamethasone showed an acceptable safety profile, and AEs were well managed according to study protocols and established guidelines.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.12903","type":"journal-article","created":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T14:48:38Z","timestamp":1494859718000},"page":"199-206","source":"Crossref","is-referenced-by-count":23,"title":["Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low\u2010dose dexamethasone: A pooled analysis"],"prefix":"10.1111","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-8746","authenticated-orcid":false,"given":"Philippe","family":"Moreau","sequence":"first","affiliation":[{"name":"University Hospital H\u00f4tel\u2010Dieu  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Siegel","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center Hackensack University Medical Center  Hackensack NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"Bologna University School of Medicine  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[{"name":"University of Milano, Fondazione IRCCS Istituto Nazionale de Tumori  Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[{"name":"University Hospital of Tuebingen  Tuebingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[{"name":"University Hospital Leuven  Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"O'Gorman","sequence":"additional","affiliation":[{"name":"Mater Misericordiae University Hospital University College Dublin  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Song","sequence":"additional","affiliation":[{"name":"Vancouver General Hospital  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Chen","sequence":"additional","affiliation":[{"name":"Princess Margaret Hospital  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Bahlis","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Center University of Calgary  Calgary Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[{"name":"Institut Catal\u00e0 d'Oncologia, Institut Josep Carreras Hospital Germans Trias i Pujol  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hansson","sequence":"additional","affiliation":[{"name":"Skane University Hospital Lund University  Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kaiser","sequence":"additional","affiliation":[{"name":"The Royal Marsden Hospital  Surrey UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pekka","family":"Anttila","sequence":"additional","affiliation":[{"name":"Helsinki University and Helsinki University Hospital Comprehensive Cancer  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinier","family":"Raymakers","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Joao","sequence":"additional","affiliation":[{"name":"Hemato\u2010Oncology Department Champalimaud Foundation for the Unknown and Faculdade de Ci\u00eancias M\u00e9dicas\u2010NOVA University  Lisbon Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[{"name":"St James's Institute of Oncology St James's University Hospital  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Sternas","sequence":"additional","affiliation":[{"name":"Celgene Corporation  Summit NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsvetan","family":"Biyukov","sequence":"additional","affiliation":[{"name":"Celgene International S\u00e0rl  Boudry Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Slaughter","sequence":"additional","affiliation":[{"name":"Celgene International S\u00e0rl  Boudry Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Hong","sequence":"additional","affiliation":[{"name":"Celgene Corporation  Summit NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Herring","sequence":"additional","affiliation":[{"name":"Celgene Corporation  Summit NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yu","sequence":"additional","affiliation":[{"name":"Celgene Corporation  Summit NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Zaki","sequence":"additional","affiliation":[{"name":"Celgene Corporation  Summit NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"San\u2010Miguel","sequence":"additional","affiliation":[{"name":"Clinica Universidad de Navarra CIMA, IDISNA  Pamplona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,14]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.356"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S110189"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.148882"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2014.966074"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.60"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2012.05.003"},{"key":"e_1_2_8_8_1","unstructured":"NCCN Clinical practice guidelines in oncology.Prevention and Treatment of Cancer\u2010Related Infections. V2. 2016.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/infections.pdf2016; Accessed November 18 2016."},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2016-0184"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-568923"},{"key":"e_1_2_8_11_1","unstructured":"NCCN Clinical practice guidelines in oncology.Multiple Myeloma. V1.2017.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf2017; Accessed November 18 2016."},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.346"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.117176"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1086\/605664"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.107714"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.236"},{"key":"e_1_2_8_17_1","volume-title":"[Summary of Product Characteristics]","author":"Imnovid (pomalidomide)","year":"2016"},{"key":"e_1_2_8_18_1","volume-title":"[Prescribing Information]","author":"Pomalyst (pomalidomide)","year":"2016"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-450742"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-452375"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-538835"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-700872"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1177181"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.137083"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200312"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.48.7934"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24129"},{"key":"e_1_2_8_30_1","first-page":"331","article-title":"European post\u2010approval safety study (PASS) of relapsed\/refractory multiple myeloma (RRMM): safety, including SPM, in\u00a0a large cohort\u00a0of patients treated with lenalidomide, thalidomide, and bortezomib","volume":"98","author":"Cavo M","year":"2013","journal-title":"Haematologica"},{"key":"e_1_2_8_31_1","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1182\/blood.V128.22.5680.5680","article-title":"European post\u2010approval safety study (registry) of relapsed\/refractory multiple myeloma (RRMM): safety of patients treated with pomalidomide","volume":"128","author":"Di Raimondo F","year":"2016","journal-title":"Blood"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.12.007"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12903","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12903","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T07:08:08Z","timestamp":1696316888000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,14]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1111\/ejh.12903"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12903","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,14]]}}}